For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

Semaglutide

Also known as: Semaglutide (GLP-1 agonist)

Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management. It mimics the incretin hormone GLP-1 to regulate appetite and glucose metabolism.

Real-time market data

Pricing for Semaglutide

Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.

Independent evidence

COAs for Semaglutide

86 third-party tests across 16 vendors. Each card links to the full report.

All 86 COAs for Semaglutide →
Measured purity 99.0%–100.0% across 50 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.86 %
Apr 2026
Janoshik Analytical · HPLC

For

Semaglutide

by Prime Peptides· batch 3022026SM

Aggregated · 3rd-party listing
99.75 %
Apr 2026
Janoshik Analytical · HPLC

For

Semaglutide

by Prime Peptides· batch 3142026SM

Aggregated · 3rd-party listing
99.17 %
Apr 2026
Janoshik Analytical · HPLC

For

Semaglutide

by Prime Peptides· batch 2242026SM

Aggregated · 3rd-party listing
99.00 %
Apr 2026
Ethos Analytics · HPLC

For

Semaglutide

by OROS Research· batch OR-LPGLPS10-426-B3

Aggregated · 3rd-party listing
99.68 %
Apr 2026
Janoshik Analytical · HPLC

For

Semaglutide

by Prime Peptides· batch 3272026SM

Aggregated · 3rd-party listing
99.63 %
Apr 2026
Janoshik Analytical · HPLC

For

Semaglutide

by Prime Peptides· batch 3222026SX

Aggregated · 3rd-party listing
99.80 %
Apr 2026
Freedom Diagnostics · HPLC

For

Semaglutide

by Blank Peptides· batch 665394

Aggregated · 3rd-party listing
99.41 %
Mar 2026
AccumarkLabs · HPLC

For

Semaglutide

by Prime Peptides· batch 2182026SM

Aggregated · 3rd-party listing
99.02 %
Mar 2026
Vanguard Laboratory · HPLC

For

Semaglutide

by Prime Peptides· batch 2122026SM

Aggregated · 3rd-party listing
99.45 %
Mar 2026
Janoshik Analytical · HPLC

For

Semaglutide

by Qihang Peptide· batch 3

Aggregated · 3rd-party listing
99.76 %
Feb 2026
Vanguard Laboratory · HPLC

For

Semaglutide

by Reta One Labs· batch SM100326

Aggregated · 3rd-party listing
99.31 %
Feb 2026
Vanguard Laboratory · HPLC

For

Semaglutide

by Reta One Labs· batch SM200326

Aggregated · 3rd-party listing
99.52 %
Feb 2026
Janoshik Analytical · HPLC

For

Semaglutide

by Prime Peptides· batch 1052026SM

Aggregated · 3rd-party listing
99.48 %
Feb 2026
Freedom Diagnostics · HPLC

For

Semaglutide

by Simple Peptide· batch 51495-P

Aggregated · 3rd-party listing
99.76 %
Jan 2026
Freedom Diagnostics · HPLC

For

Semaglutide

by Simple Peptide· batch 41704

Aggregated · 3rd-party listing
99.79 %
Jan 2026
Janoshik Analytical · HPLC

For

Semaglutide

by Prime Peptides· batch 11092025SM

Aggregated · 3rd-party listing
99.47 %
Dec 2025
Janoshik Analytical · HPLC

For

Semaglutide

by Skye Peptides· batch SM25-10-003

Aggregated · 3rd-party listing
99.12 %
Dec 2025
Janoshik Analytical · HPLC

For

Semaglutide

by Skye Peptides· batch SM25-05-003

Aggregated · 3rd-party listing
99.94 %
Dec 2025
Freedom Diagnostics · HPLC

For

Semaglutide

by Simple Peptide· batch OS10-12082025-J

Aggregated · 3rd-party listing
99.43 %
Dec 2025
Janoshik Analytical · HPLC

For

Semaglutide

by Crystal Peptides· batch cmojgrlr4004p9grxx3xy2hum

Aggregated · 3rd-party listing
99.91 %
Nov 2025
Freedom Diagnostics · HPLC

For

Semaglutide

by Simple Peptide· batch GS10-11202025-J

Aggregated · 3rd-party listing
99.62 %
Nov 2025
Janoshik Analytical

For

Semaglutide

by Reta Peptide

Aggregated · 3rd-party listing
99.62 %
Nov 2025
Janoshik Analytical

For

Semaglutide

by Reta Peptide

Aggregated · 3rd-party listing
99.02 %
Oct 2025
Janoshik Analytical · HPLC

For

Semaglutide

by Skye Peptides· batch SMX25-30-003

Research depth

35 citations indexed for Semaglutide

All research on Semaglutide →

cohort · 2026

Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials

Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.

Study · 2026

Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes

Aims Semaglutide, a GLP-1 receptor agonist, has demonstrated significant weight loss benefits for patients with overweight or obesity in both oral and subcutaneous (s.c.) formulations.

animal · 2026

Gut-Derived FGF15 Modulates Lean Mass, Bone, and Bile Acid Responses to Weight Loss

Dietary, surgical, and pharmacological methods can effectively reduce body weight; however, rapid weight loss can also be accompanied by a loss of lean mass.

Study · 2026

Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis

Objective People receiving dialysis are at high risk of cardiovascular and all-cause mortality. Semaglutide reduces major adverse cardiovascular events (MACE) in people with type 2 diabetes (T2D) and those without T2D with obesity and high cardiovascular risk.

rct · 2026

Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease

Background Diabetic kidney disease (DKD) is a common complication of type 2 diabetes mellitus and an important cause of end-stage renal disease. Metabolic dysfunction, albuminuria, and chronic low-grade inflammation characterize early DKD, leading to progressive renal impairment.

Study · 2026

Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey

Introduction 'Food noise', persistent and intrusive thoughts about food that can disrupt daily life, has emerged as a concern for individuals with obesity, and often impacts quality of life. Recent anecdotal reports suggest that glucagon-like peptide-1 receptor agonists, such as semaglutide, may reduce food noise.